Top Page
Arcus Biosciences
(NYSE:RCUS)
Arcus Biosciences (RCUS) vs. SPDR S&P 500 ETF (SPY)
Arcus Biosciences Business Overview & Revenue Model
Arcus Biosciences Key Performance Indicators (KPIs)
Breaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments.
Main Street DataArcus Biosciences Earnings Call Summary
Arcus Biosciences Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 240.00M | 258.00M | 117.00M | 112.00M | 383.00M | 78.00M |
| Gross Profit | 238.00M | -190.00M | 117.00M | 112.00M | 383.00M | 78.00M |
| EBITDA | -323.00M | -269.00M | -291.00M | -258.00M | 59.00M | -120.00M |
| Net Income | -349.00M | -283.00M | -307.00M | -267.00M | 53.00M | -123.00M |
Balance Sheet | ||||||
| Total Assets | 974.00M | 1.15B | 1.09B | 1.34B | 1.59B | 772.29M |
| Cash, Cash Equivalents and Short-Term Investments | 831.00M | 978.00M | 759.00M | 1.14B | 681.30M | 735.09M |
| Total Debt | 98.00M | 159.00M | 11.00M | 120.00M | 116.89M | 15.24M |
| Total Liabilities | 538.00M | 665.00M | 633.00M | 688.00M | 750.45M | 269.99M |
| Stockholders Equity | 436.00M | 485.00M | 462.00M | 657.00M | 841.45M | 502.30M |
Cash Flow | ||||||
| Free Cash Flow | -464.00M | -176.00M | -330.00M | 426.00M | -282.25M | 108.11M |
| Operating Cash Flow | -462.00M | -170.00M | -306.00M | 438.00M | -256.17M | 111.17M |
| Investing Cash Flow | 299.00M | -84.00M | 194.00M | -413.00M | -3.87M | -434.37M |
| Financing Cash Flow | 200.00M | 277.00M | 33.00M | 33.00M | 237.34M | 438.68M |
Arcus Biosciences Technical Analysis
Arcus Biosciences Risk Analysis
Arcus Biosciences Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $627.88M | ― | -43.63% | ― | ― | -13.05% | |
56 Neutral | $2.44B | ― | -68.13% | ― | -8.75% | -8.79% | |
52 Neutral | ― | ― | ― | ― | 271.44% | 26.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $1.77B | ― | -32.63% | ― | ― | -123.65% | |
42 Neutral | $663.47M | ― | -96.24% | ― | ― | -15.77% | |
33 Underperform | $1.06B | ― | -109.12% | ― | ― | 7.58% |
Arcus Biosciences Corporate Events
Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing innovative therapies for cancer, inflammatory, and autoimmune diseases. The company is known for its differentiated molecules and combination therapies aimed at improving patient outcomes.
Arcus Biosciences is conducting a clinical study titled ‘A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies.’ The study aims to assess the safety and tolerability of AB801, a new drug, in patients with advanced cancers, and to determine the recommended dose for further trials. This study is significant as it could lead to new treatment options for patients with limited alternatives.
Arcus Biosciences is conducting a Phase 3 clinical trial titled ‘A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma.’ The study aims to evaluate progression-free survival in patients with advanced or metastatic clear cell renal cell carcinoma who have progressed after prior immunotherapy.
Arcus Biosciences is conducting a Phase 1 clinical study titled A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors. The study aims to evaluate the safety and tolerability of casdatifan, both as a standalone treatment and in combination with cabozantinib or zimberelimab, for patients with clear cell renal cell carcinoma and other solid tumors. This research is significant as it explores new therapeutic options for these challenging cancer types.
On October 12, 2025, Arcus Biosciences announced the first overall survival results from the Phase 2 EDGE-Gastric study, showing promising efficacy of the domvanalimab plus zimberelimab and chemotherapy regimen in patients with advanced gastric and esophageal cancers. The study, which evaluated 41 patients, demonstrated sustained efficacy across all PD-L1 subgroups with a median overall survival of 26.7 months and a favorable safety profile, indicating potential advancements in cancer treatment options.
The most recent analyst rating on (RCUS) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
On October 6, 2025, Arcus Biosciences presented updated data from its ARC-20 Phase 1/1b study, which evaluates the efficacy and safety of casdatifan in patients with metastatic clear cell renal cell carcinoma. The data, as of August 15, 2025, showed promising results in terms of progression-free survival and disease control rates, with no unexpected safety concerns. Additionally, Arcus announced plans to expand into immunology and inflammation, with potential new drug candidates targeting conditions such as atopic dermatitis, rheumatoid arthritis, and multiple sclerosis, aiming to initiate clinical studies in 2026.
The most recent analyst rating on (RCUS) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Arcus Biosciences stock, see the RCUS Stock Forecast page.
In a significant advancement for cancer treatment, Gilead Sciences and Arcus Biosciences are conducting a Phase 3 study titled A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations. The study aims to compare the overall survival rates of patients receiving zimberelimab and domvanalimab in combination with chemotherapy against those receiving pembrolizumab with chemotherapy.
Gilead Sciences and Arcus Biosciences are collaborating on a clinical study titled A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer. The study aims to assess the antitumor activity and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer, a significant area of unmet medical need.
The clinical study titled ‘A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)’ aims to assess the safety and preliminary clinical activity of various treatment combinations, with and without chemotherapy, in patients with advanced gastric, GEJ, and esophageal adenocarcinoma. This study is significant as it explores potential new treatment options for these challenging cancers.
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies through differentiated molecules and combination treatments. In its latest earnings report for the second quarter of 2025, Arcus Biosciences highlighted significant progress in its clinical trials and financial performance. The company initiated two major studies, PEAK-1 and eVOLVE-RCC02, aimed at evaluating its promising HIF-2a inhibitor, casdatifan, in various settings of metastatic clear cell renal cell carcinoma (ccRCC). Additionally, Arcus reported a substantial increase in revenue, primarily due to a cumulative catch-up related to its collaboration with Gilead Sciences. The company’s financial health remains robust, with $927 million in cash and equivalents, ensuring continued support for its pipeline advancements. Looking ahead, Arcus is poised to deliver key data readouts in the coming months, maintaining a strong focus on its strategic priorities and collaborations to drive future growth.
Arcus Biosciences is currently conducting a Phase 1 clinical study titled A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors. The study aims to assess the safety, tolerability, and pharmacokinetic profile of AB521, also known as casdatifan, both as a standalone treatment and in combination with other therapies for patients with clear cell renal cell carcinoma (ccRCC) and other solid tumors. This study is significant as it explores potential new treatment options for these challenging cancer types.
Arcus Biosciences is conducting a Phase 3 trial titled ‘A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma.’ The study aims to compare overall survival rates between patients receiving quemliclustat with chemotherapy and those receiving a placebo with chemotherapy, highlighting its significance in potentially improving treatment outcomes for metastatic pancreatic cancer.
Gilead Sciences and Arcus Biosciences are collaborating on a Phase 2 study titled A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer. The study aims to assess the safety and efficacy of various immunotherapy combinations in treating PD-L1 positive metastatic non-small cell lung cancer, highlighting its significance in advancing cancer treatment options.
Arcus Biosciences is conducting a Phase 1/1b study titled A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies. The study aims to evaluate the safety and tolerability of AB801, a drug for advanced cancers, and to determine the recommended dose for further research. This study is significant as it could lead to new treatment options for patients with limited alternatives.
Arcus Biosciences is conducting a Phase 1/1b clinical study titled A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies. The primary goal is to assess the safety and tolerability of AB598 in patients with advanced cancers, which is crucial for developing new cancer treatments.
The recent clinical study update from Arcus Biosciences and Gilead Sciences focuses on evaluating the efficacy and safety of etrumadenant-based treatment combinations in patients with metastatic colorectal cancer. Officially titled ‘A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer,’ the study aims to explore new therapeutic options for this challenging condition.